Epidemiology Data

May 2022
For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this presentation. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This presentation is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this presentation, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

This presentation contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

IMPORTANT NOTICE
OVERVIEW OF EPIDEMIOLOGY DATA

ONCOLOGY

GASTROENTEROLOGY (GI)

RARE GENETIC & HEMATOLOGY
## EPIDEMIOLOGY – NINLARO, ALUNBRIG, ADCETRIS & ICLUSIG

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Total Global Eligible Population (March 2022)</th>
<th>Geographies included</th>
</tr>
</thead>
<tbody>
<tr>
<td>NINLARO</td>
<td>R/R 2L+ Multiple Myeloma</td>
<td>~114,000&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Japan, US, EU5, China</td>
</tr>
<tr>
<td>ALUNBRIG</td>
<td>ALK+ NSCLC</td>
<td>~36,000&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Japan, US, EU5, China</td>
</tr>
<tr>
<td>ADCETRIS</td>
<td>HL – Front Line, ASCT Consolidation, 2L+; TCL - PTCL &amp; R/R CTCL</td>
<td>~22,000&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Japan, EU5, China</td>
</tr>
<tr>
<td>ICLUSIG</td>
<td>2L+ CML, ALL</td>
<td>~5,200&lt;sup&gt;4&lt;/sup&gt;</td>
<td>US</td>
</tr>
<tr>
<td>EXKIVITY</td>
<td>2L+ EGFR Exon20 Insertion+ NSCLC</td>
<td>~6,200&lt;sup&gt;5&lt;/sup&gt;</td>
<td>Japan, US, EU5</td>
</tr>
</tbody>
</table>

1. R/R 2L+ MM label eligible patients; 2. ALK+ tested patients; 3. CD30+ label eligible patients - regulatory approval includes Stage IV/ITT Front Line Patients and High Risk HL consolidation patients; 4. 2L+ CP-CML, 3L+ AP/BP-CML, T315I+ CML, Ph+ ALL S. EGFR Exon20 insertion+ mNSCLC patients whose disease has progressed on or after platinum-based chemotherapy.

Source: Takeda estimates. EU5 = France, Spain, Germany, Italy, UK.
OVERVIEW OF EPIDEMIOLOGY DATA

ONCOLOGY

GASTROENTEROLOGY (GI)

RARE GENETIC & HEMATOLOGY
**Epidemiology Ulcerative Colitis (UC)**

- **Diagnosed Prevalence**
  - Japan: 329K
  - GEM (incl. China): 1,434K
  - EUCAN: 1,207K
  - US: 786K
  - Total: ~3,760K

- **Treated**
  - Japan: 315K
  - GEM (incl. China): 1,291K
  - EUCAN: 924K
  - US: 770K
  - Total: ~3,300K

- **Patients on Biologic Therapies**
  - Japan: ~420K
  - GEM (incl. China): 28K
  - EUCAN: 179K
  - US: 119K
  - Total: ~420K

Source: Takeda estimates. Note: Numbers are rounded.
EPIDEMIOLOGY CROHN’S DISEASE (CD)

Diagnosed Prevalence
- ~2,370K
  - 847K
  - 1,053K
  - 413K

Treated
- ~2,110K
  - 804K
  - 878K
  - 372K

Patients on biologic therapies
- ~680K
  - 247K
  - 280K
  - 122K

Source: Takeda estimates. Note: Numbers are rounded.
Crohn's Disease (CD) Patients

~1,960K

1,053K

~847K

Japan

EUCAN

US

CD Patients with Perianal Fistula

~324K

119K

178K

Complex Perianal Fistula (CPF) Patients

~213K

60K

139K

Source: Takeda estimates. Note: Numbers are rounded.
EPIDEMIOLOGY HEREDITARY ANGIOEDEMA

Prevalence: 70K
Diagnosed: 24K
Treated: 20K

Source: Takeda estimates. Note: Numbers are rounded.
EPIDEMIOLOGY GAUCHER’S DISEASE: GLOBAL, CHINA/INDIA NOT INCLUDED

~34-35K prevalent patients

~10K diagnosed patients (30%)

~24K un-diagnosed patients (70%)

Source: Takeda estimates. Note: Numbers are rounded.
EPIDEMIOLOGY FABRY’S DISEASE: EX-US REGION, CHINA/INDIA NOT INCLUDED

Prevalence

~53-54K prevalent Fabry patients

Diagnosis

~14K diagnosed Fabry patients (26%)

~40K un-diagnosed patients (74%)

Source: Takeda estimates. Note: Numbers are rounded.
Epidemiology: Hunter’s Disease
Global, India/China Not Included

MPS II Patients

- Prevalence: 5K
- Diagnosed: 2-3K
- Treated: 2K

Source: Takeda estimates. Note: Numbers are rounded.
Hemophilia A without inhibitors

~142K
69K
5K
50K
18K

Prevalence

~116K
46K
5K
48K
17K

Diagnosed

~92K
40K
5K
30K
17K

Treated

GEM excl. CN/IN
Japan
EUCAN
US

Source: Takeda estimates. Note: Numbers are rounded.
EPIDEMIOLOGY
CYTOMEGALOVIRUS (CMV) INFECTION IN POST-TRANSPLANT

Source: Takeda estimates. Note: Numbers are rounded.

1/4 of transplant patients experience CMV infections

Legend:
- Global
- Heart
- Kidney
- Lung
- Liver
- Pancreas

- Solid Organ Transplants
  - Liver: 65.0% (≈99k)
  - Kidney: 23.0% (≈34k)
  - Heart: 6.0% (≈50k)
  - Lung: 4.0% (≈99k)

- Allogeneic Hemopoietic Stem Cell Transplant
  - Kidney: 2.0% (≈34k)

- Autologous Hemopoietic Stem Cell Transplant
  - Kidney: 2.0% (≈50k)

Adult Transplantations Performed Annually

- Total: 183k

- Solid Organ Transplants: 143k
  - Liver: 65.0% (≈99k)
  - Kidney: 23.0% (≈34k)
  - Heart: 6.0% (≈50k)
  - Lung: 4.0% (≈99k)

- Allogeneic Hemopoietic Stem Cell Transplant: 34k
- Autologous Hemopoietic Stem Cell Transplant: 50k

Source: Takeda estimates. Note: Numbers are rounded.